Fig. 7
Hypoxia promotes HCC progression through MRVI1-AS1/SKA1 pathway. A, B Transwell assays were performed by using the indicated MHCC-97H and Hep3B subclones which were incubated in 20% O2 or 1% O2 for 24 h (mean ± SD; n = 3). **P < 0.01, ***P < 0.001, two-way ANOVA. C, D Wound healing assays were performed by using the indicated MHCC-97H and Hep3B subclones which were incubated in 20% O2 or 1% O2 for 24 h (mean ± SD; n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA. E, F MTT assays were performed by using the indicated MHCC-97H and Hep3B subclones which were incubated in 20% O2 or 1% O2 (mean ± SD; n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA. G, H EdU assays were performed by using the indicated MHCC-97H and Hep3B subclones which were incubated in 20% O2 or 1% O2 for 24 h (mean ± SD; n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA